LaunXP Biomedical Co., Ltd.

LaunXP Biomedical Co., Ltd. is a biotechnology company headquartered in Taichung, Taiwan, specializing in the development of innovative cancer therapies. Established in 2015, LaunXP focuses on research and development of anti-cancer and antiproliferative drugs, primarily leveraging virus-like nanoparticles and targeted nanoparticles to develop new medicines. The company’s key projects include novel multi-target kinase inhibitors, such as LXPA1788, and specialized agents like LXPA1988, which targets fms-like tyrosine kinase 3 (FLT3) for acute myeloid leukemia, as well as several other proprietary compounds with unique structures or new indications. LaunXP operates within the biotechnology and medical research sector, contributing to advancements in oncology by addressing unmet medical needs in cancer treatment. The company also engages in collaborative ventures, exemplified by a development agreement with Apollomics to advance combination therapies for non-small cell lung cancer in certain Asian markets. Through its emphasis on innovative drug discovery and clinical development, LaunXP Biomedical plays a growing role in the regional and global biopharmaceutical landscape, aiming to expand the therapeutic options for cancer patients.